Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Post-authorisation Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation, Including a Non-comparative Concurrent Reference Cohort

NCT05937750 is registered in ClinicalTrials.gov with Hansa Biopharma AB as lead sponsor.

NCT NCT05937750
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05937750 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Post-authorisation Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation, Including a Non-comparative Concurrent Reference Cohort
Lead sponsor
Hansa Biopharma AB
Phase
Phase 3
Overall status
Active, not recruiting
Start date
July 3, 2023
Completion date
April 30, 2030
Enrollment
150 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

long term efficacy and safety